FDA Approves Dual-Chamber Syringe for Abilify Maintena (aripiprazole) for Schizophrenia

In continuation of my update on aripiprazole

We know that, Aripiprazole (brand names: Abilify, Aripiprex) is a atypical antipsychotic. It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder (as an add on to other treatment),tic disorders, and irritability associated with autism. 

It was approved by the U.S. Food and Drug Administration (FDA) for schizophrenia on November 15, 2002 and the European Medicines Agency on 4 June 2004; for acute manic and mixed episodes associated with bipolar disorder on October 1, 2004; as an adjunct for major depressive disorder on November 20, 2007; and to treat irritability in children with autism on 20 November 2009.  Likewise it was approved for use as a treatment for schizophrenia by the TGA of Australia in May 2003.  It is a partial dopamine agonist

Aripiprazole was developed by Otsuka in Japan, and in the United States, Otsuka America markets it jointly with Bristol-Myers Squibb.

FDA Approves Dual-Chamber Syringe for Abilify Maintena (aripiprazole) for Schizophrenia